Takip et
Aaron Cravens
Aaron Cravens
CEO, Revel Pharmaceuticals
revelpharmaceuticals.com üzerinde doğrulanmış e-posta adresine sahip - Ana Sayfa
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Synthetic biology strategies for microbial biosynthesis of plant natural products
A Cravens, J Payne, CD Smolke
Nature communications 10 (1), 2142, 2019
3082019
Complete biosynthesis of noscapine and halogenated alkaloids in yeast
Y Li, S Li, K Thodey, I Trenchard, A Cravens, CD Smolke
Proceedings of the National Academy of Sciences 115 (17), E3922-E3931, 2018
2692018
Polymerase-guided base editing enables in vivo mutagenesis and rapid protein engineering
A Cravens, OK Jamil, D Kong, JT Sockolosky, CD Smolke
Nature Communications 12 (1), 1579, 2021
1002021
Multicolor super-resolution DNA imaging for genetic analysis
M Baday, A Cravens, A Hastie, HJ Kim, DE Kudeki, PY Kwok, M Xiao, ...
Nano letters 12 (7), 3861-3866, 2012
492012
Interactions between fengycin and model bilayers quantified by coarse-grained molecular dynamics
JN Horn, A Cravens, A Grossfield
Biophysical journal 105 (7), 1612-1623, 2013
422013
Engineering a microbial platform for de novo biosynthesis of diverse methylxanthines
M McKeague, YH Wang, A Cravens, MN Win, CD Smolke
Metabolic engineering 38, 191-203, 2016
412016
Biosynthesis of tetrahydropapaverine and semisynthesis of papaverine in yeast
OK Jamil, A Cravens, JT Payne, CY Kim, CD Smolke
Proceedings of the National Academy of Sciences 119 (33), e2205848119, 2022
132022
Annotating protein secondary structure from sequence
A Cravens, C Probert
Stanford University, 2015
22015
Exploring the Mechanisms of Antimicrobial Lipopeptides with Molecular Simulation
A Grossfield, JN Horn, TD Romo, D Lin, A Cravens
Biophysical Journal 104 (2), 9a-10a, 2013
2013
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–9